Literature DB >> 25377666

Resolute efforts to cure hepatitis C: Understanding patients' reasons for completing antiviral treatment.

Jack A Clark1, Allen L Gifford2.   

Abstract

Antiviral treatment for hepatitis C is usually difficult, demanding, and debilitating and has long offered modest prospects of successful cure. Most people who may need treatment have faced stigma of an illness associated with drug and alcohol misuse and thus may be deemed poor candidates for treatment, while completing a course of treatment typically calls for resolve and responsibility. Patients' efforts and their reasons for completing treatment have received scant attention in hepatitis C clinical policy discourse that instead focuses on problems of adherence and patients' expected failures. Thus, we conducted qualitative interviews with patients who had recently undertaken treatment to explore their reasons for completing antiviral treatment. Analysis of their narrative accounts identified four principal reasons: cure the infection, avoid a bad end, demonstrate the virtue of perseverance through a personal trial, and achieve personal rehabilitation. Their reasons reflect moral rationales that mark the social discredit ascribed to the infection and may represent efforts to restore creditable social membership. Their reasons may also reflect the selection processes that render some of the infected as good candidates for treatment, while excluding others. Explication of the moral context of treatment may identify opportunities to support patients' efforts in completing treatment, as well as illuminate the choices people with hepatitis C make about engaging in care. © US Government 2014.

Entities:  

Keywords:  ethnography; health policy; illness behavior

Mesh:

Substances:

Year:  2014        PMID: 25377666     DOI: 10.1177/1363459314555237

Source DB:  PubMed          Journal:  Health (London)        ISSN: 1363-4593


  5 in total

Review 1.  Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world.

Authors:  Sarah R Donaldson; Andrew Radley; John F Dillon
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-06-08

2.  Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).

Authors:  Matthew Hickman; John F Dillon; Lawrie Elliott; Daniela De Angelis; Peter Vickerman; Graham Foster; Peter Donnan; Ann Eriksen; Paul Flowers; David Goldberg; William Hollingworth; Samreen Ijaz; David Liddell; Sema Mandal; Natasha Martin; Lewis J Z Beer; Kate Drysdale; Hannah Fraser; Rachel Glass; Lesley Graham; Rory N Gunson; Emma Hamilton; Helen Harris; Magdalena Harris; Ross Harris; Ellen Heinsbroek; Vivian Hope; Jeremy Horwood; Sarah Karen Inglis; Hamish Innes; Athene Lane; Jade Meadows; Andrew McAuley; Chris Metcalfe; Stephanie Migchelsen; Alex Murray; Gareth Myring; Norah E Palmateer; Anne Presanis; Andrew Radley; Mary Ramsay; Pantelis Samartsidis; Ruth Simmons; Katy Sinka; Gabriele Vojt; Zoe Ward; David Whiteley; Alan Yeung; Sharon J Hutchinson
Journal:  BMJ Open       Date:  2019-09-24       Impact factor: 2.692

3.  "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.

Authors:  Trevor Goodyear; Helen Brown; Annette J Browne; Peter Hoong; Lianping Ti; Rod Knight
Journal:  Int J Equity Health       Date:  2021-03-19

4.  Transformation of identity in substance use as a pathway to recovery and the potential of treatment for hepatitis C: a systematic review protocol.

Authors:  Sarah R Donaldson; Andrew Radley; John F Dillon
Journal:  BMJ Open       Date:  2022-02-07       Impact factor: 2.692

5.  The Lived Experience of Patients Utilizing Second-Generation Direct-Acting Antiviral for Treatment of Chronic Hepatitis C Virus Infection: A Phenomenological Analysis.

Authors:  Yone de Almeida Nascimento; Luciana Diniz Silva; Djenane Ramalho de Oliveira
Journal:  Int J Environ Res Public Health       Date:  2022-10-01       Impact factor: 4.614

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.